Biotech company Immutep
(ASX:IMM) today announces more mature data relating to Part B of its ongoing phase I TACTImel clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in patients with melanoma.
Consistent with previous data reported at 6 months of combination treatment, patients in Part B continue to report positive results in terms of tumour reductions after 9 months of treatment.
The data will be presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 in London today.
The ongoing TACTI-mel trial evaluates the combination of efti with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 24 patients with unresectable or metastatic melanoma.
Shares in Immutep
(ASX:IMM) are trading 3.45 per cent higher at 3 cents.
